Body
Dual-action therapy with medical oversight. A clear, evidence-aware guide to candidacy, treatment, recovery, limitations and next steps.
Healthy change
Physician-led guidance brings your goals, health history and realistic expectations into one thoughtful plan.
The Short Answer
Tirzepatide activates GIP and GLP-1 receptors. FDA-approved Zepbound is indicated for chronic weight management in eligible adults, with additional labeled use for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside nutrition and physical activity.
Candidacy
Eligibility depends on current labeling, BMI, related conditions, medications and risk profile. The prescriber confirms the indication, coordinates diabetes medicines and assesses gastrointestinal, gallbladder and thyroid history.
Tirzepatide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 and with serious hypersensitivity. Pregnancy and important gastrointestinal, pancreatic, gallbladder, kidney, eye and medication issues require review.
At a Glance
These are practical planning ranges, not promises. Your consultation determines the exact plan.
Initial visit about 30–60 minutes; follow-ups are shorter
Weekly subcutaneous injection as prescribed
No procedural downtime; gastrointestinal effects can limit activity
Appetite or weight change evolves over weeks to months
Long-term therapy may be needed; weight regain can occur after stopping
Ongoing titration and monitoring
Your Visit
The clinician reviews weight history, health conditions, medications, pregnancy plans and labs.
If eligible, Zepbound or another appropriate FDA-approved product is prescribed and titrated according to labeling and tolerability.
Weight, nutrition, strength, adverse effects and related conditions are monitored. The plan changes when benefit, risk or access changes.
Informed Choice
Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort and injection-site reactions. Important risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal effects, allergy and low blood sugar with certain diabetes drugs. Labeling includes a boxed thyroid C-cell tumor warning.
Clinical Judgment
Safe care requires more than escalating a dose. Experienced supervision verifies sourcing, coordinates diabetes or sleep-apnea treatment, protects nutrition and lean mass, and recognizes when side effects or inadequate benefit require a change.
Access & Cost
Consultations and follow-up may be in-office or by telehealth for patients physically located in Texas, North Carolina or South Carolina, subject to eligibility and law. Labs or in-person assessment may be required.
Pricing: Consultation required. Medication cost varies by product, insurance, pharmacy and dose. Coverage and availability cannot be guaranteed.
Common Questions
No. Compounded drugs are not FDA-approved. FDA has raised concerns about unapproved GLP-1 products, dosing errors and quality.
Both contain tirzepatide, but they have different FDA-approved indications and labeling. The prescribed product must match the diagnosis and treatment plan.
Do not combine or switch medicines without prescriber direction. Zepbound labeling limits coadministration with other tirzepatide or GLP-1 products.
Sources & Medical Review
